These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 21439443)

  • 21. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy of multiple sclerosis--current practice and future directions.
    Tullman MJ; Lublin FD; Miller AE
    J Rehabil Res Dev; 2002; 39(2):273-85. PubMed ID: 12051470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies].
    Ouallet JC
    Rev Neurol (Paris); 2010 Jan; 166(1):21-31. PubMed ID: 19596382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postmarketing evidence of disease-modifying drugs in multiple sclerosis.
    Trojano M; Paolicelli D; Fuiani A; Pellegrini F; Iaffaldano P; Direnzo V; D'Onghia M
    Neurol Sci; 2008 Sep; 29 Suppl 2():S225-6. PubMed ID: 18690499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-specific immunosuppressants in the treatment of multiple sclerosis.
    Confavreux C; Vukusic S
    Clin Neurol Neurosurg; 2004 Jun; 106(3):263-9. PubMed ID: 15177781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple sclerosis: a supplement on the disease state, current therapies, and investigational treatments.
    Mahdavian S; Dike U; Bryant A; Davison C; Ghazvini P; Hill A
    J Pharm Pract; 2010 Apr; 23(2):91-100. PubMed ID: 21507801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A practical approach to immunomodulatory therapy for multiple sclerosis.
    Burks JS
    Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
    J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management.
    Wingerchuk DM
    Expert Rev Neurother; 2006 Mar; 6(3):333-46. PubMed ID: 16533138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study.
    Evans C; Tam J; Kingwell E; Oger J; ; Tremlett H
    Clin Ther; 2012 Feb; 34(2):341-50. PubMed ID: 22296946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current therapeutic recommendations in multiple sclerosis.
    Berger T
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S37-45. PubMed ID: 20106347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural history of multiple sclerosis: long-term prognostic factors.
    Renoux C
    Neurol Clin; 2011 May; 29(2):293-308. PubMed ID: 21439442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of multiple sclerosis. The present and the future. Study Group on Diagnosis and Therapy of Multiple Sclerosis].
    Cazzato G; Antonello RM; Zorzon M; Torre P; Zivadinov R; Moretti R; Bragadin LM; De Masi R; Nasuelli D
    Recenti Prog Med; 1999 Oct; 90(10):538-44. PubMed ID: 10592740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognosis of the individual course of disease: the elements of time, heterogeneity and precision.
    Daumer M; Neuhaus A; Herbert J; Ebers G
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S50-5. PubMed ID: 20106349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The management of pediatric multiple sclerosis.
    Yeh EA; Weinstock-Guttman B
    J Child Neurol; 2012 Nov; 27(11):1384-93. PubMed ID: 22914373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current treatment for multiple sclerosis].
    Papeix C; Lubetzki C; Lyon-Caen O
    Presse Med; 2010 Mar; 39(3):381-8. PubMed ID: 20106633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Current state of research on multiple sclerosis].
    Lubina-Dabrowska N; Stepień A; Chalimoniuk M
    Pol Merkur Lekarski; 2013 Mar; 34(201):135-9. PubMed ID: 23700821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple sclerosis and pregnancy.
    Tsui A; Lee MA
    Curr Opin Obstet Gynecol; 2011 Dec; 23(6):435-9. PubMed ID: 22011954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.